Summary
Soliton is a Reg A+ IPO, which means they could not get institutional investors, so they had to raise money from crowdfunding.
SOLY has put out 17 PRs since March, fueling a rally with no substance in our opinion.
SOLY’s first lock-up expiry is May 20th, and we believe it will be a bloodbath for the stock, similar to what happened to Reg A+ stock Adomani.
SOLY’s tattoo and cellulite removal devices are still in the pilot stage, unproven with few studies done.
SOLY’s biggest holder, Remeditex, has sold every significant position it has filed on sec.gov, and we doubt SOLY will be an exception.
